Methods of treatment using antibodies to neutrokine-alpha
First Claim
1. A method of treating or ameliorating a cancer comprising administering to a patient in need thereof an antibody that binds a Neutrokine-alpha polypeptide of SEQ ID NO:
- 2 in an amount effective to treat or ameliorate the cancer in the patient.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
101 Citations
9 Claims
-
1. A method of treating or ameliorating a cancer comprising administering to a patient in need thereof an antibody that binds a Neutrokine-alpha polypeptide of SEQ ID NO:
- 2 in an amount effective to treat or ameliorate the cancer in the patient.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
Specification